Gonzalo Rodriguez Tapia1, Ioannis Doumas1,2, Thierry Lejeune3,4, Jean-Gabriel Previnaire5. 1. Secteur des Sciences de la Santé, Neuro Musculo Skeletal Lab (NMSK), Institut de Recherche Expérimentale Et Clinique, Université Catholique de Louvain, Avenue Mounier 53, 1200, Brussels, Belgium. 2. Service de Médecine Physique Et Réadaptation, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium. 3. Secteur des Sciences de la Santé, Neuro Musculo Skeletal Lab (NMSK), Institut de Recherche Expérimentale Et Clinique, Université Catholique de Louvain, Avenue Mounier 53, 1200, Brussels, Belgium. thierry.lejeune@uclouvain.be. 4. Service de Médecine Physique Et Réadaptation, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium. thierry.lejeune@uclouvain.be. 5. Centre Jacques Calvé, Fondation Hopale 72, Esplanade Parmentier, 62600, Berck-sur-Mer, France.
Abstract
BACKGROUND: Recent developments in wearable powered exoskeletons (WPE) allow gait training (GT) for patients after spinal cord injury (SCI). Two recent meta-analyses on GT using WPE showed promising results for paraplegic patients (PP). To this date, there is no review focusing on tetraplegic patients (TP). OBJECTIVES: The main objective of this review was to assess feasibility and safety of GT using WPE in patients after tetraplegia. METHOD: This systematic review was performed according to PRISMA-S guidelines. Two independent reviewers searched several databases for studies on GT using WPE for TP. Primary outcomes concerned the number, type and severity of reported adverse events (AE). Secondary outcomes examined potential additional health benefits (AHB). RESULTS: Forty-one studies (6 randomized trials, 24 cohorts and 11 cases series) were selected, including 166 TP, 26 with complete lesions (AIS A) and 71 with level of injury above C6. Minor AE were reported in 17 TP, concerning cutaneous, cardiovascular or musculoskeletal systems. Occurrence of AE is significantly higher in a PP population compared to TP (p value = 0.001). Only one major AE concerned a TP. Studies of low level of evidence suggest that GT using WPE could lead to improvements in walking parameters, cardiovascular efficiency and to a reduction of spasticity. DISCUSSION AND CONCLUSION: GT using WPE is a feasible and safe intervention for TP. To minimize occurrence of AE, a good patient selection and preparation is proposed. Future clinical trials should be performed to confirm current trends in terms of efficacy and potential AHB.
BACKGROUND: Recent developments in wearable powered exoskeletons (WPE) allow gait training (GT) for patients after spinal cord injury (SCI). Two recent meta-analyses on GT using WPE showed promising results for paraplegic patients (PP). To this date, there is no review focusing on tetraplegic patients (TP). OBJECTIVES: The main objective of this review was to assess feasibility and safety of GT using WPE in patients after tetraplegia. METHOD: This systematic review was performed according to PRISMA-S guidelines. Two independent reviewers searched several databases for studies on GT using WPE for TP. Primary outcomes concerned the number, type and severity of reported adverse events (AE). Secondary outcomes examined potential additional health benefits (AHB). RESULTS: Forty-one studies (6 randomized trials, 24 cohorts and 11 cases series) were selected, including 166 TP, 26 with complete lesions (AIS A) and 71 with level of injury above C6. Minor AE were reported in 17 TP, concerning cutaneous, cardiovascular or musculoskeletal systems. Occurrence of AE is significantly higher in a PP population compared to TP (p value = 0.001). Only one major AE concerned a TP. Studies of low level of evidence suggest that GT using WPE could lead to improvements in walking parameters, cardiovascular efficiency and to a reduction of spasticity. DISCUSSION AND CONCLUSION: GT using WPE is a feasible and safe intervention for TP. To minimize occurrence of AE, a good patient selection and preparation is proposed. Future clinical trials should be performed to confirm current trends in terms of efficacy and potential AHB.
Authors: Oliver Jansen; Dennis Grasmuecke; Renate C Meindl; Martin Tegenthoff; Peter Schwenkreis; Matthias Sczesny-Kaiser; Martin Wessling; Thomas A Schildhauer; Christian Fisahn; Mirko Aach Journal: World Neurosurg Date: 2017-12-15 Impact factor: 2.104
Authors: Andrew D Delgado; Miguel X Escalon; Thomas N Bryce; William Weinrauch; Stephanie J Suarez; Allan J Kozlowski Journal: J Spinal Cord Med Date: 2019-10-11 Impact factor: 1.985
Authors: Chung-Ying Tsai; Andrew D Delgado; William J Weinrauch; Nicholas Manente; Isaiah Levy; Miguel X Escalon; Thomas N Bryce; Ann M Spungen Journal: Arch Phys Med Rehabil Date: 2019-12-28 Impact factor: 3.966
Authors: Christian Fisahn; Mirko Aach; Oliver Jansen; Marc Moisi; Angeli Mayadev; Krystle T Pagarigan; Joseph R Dettori; Thomas A Schildhauer Journal: Global Spine J Date: 2016-11-03